HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

Authors :: Hong Hoi Ting
Betül Altunay
Felix M. Mottaghy
Nicholas C.L. Wong
Hans Jürgen Biersack
Elmar Stickeler
Andreas T. J. Vogg
Mohsen Beheshti
Agnieszka Morgenroth
Source :: European Journal of Nuclear Medicine and Molecular Imaging, European journal of nuclear medicine and molecular imaging 48(5), 1371-1389 (2021). doi:10.1007/s00259-020-05094-1
Publication Year :: 2020
Publisher :: Springer Science and Business Media LLC, 2020.
Abstract: European journal of nuclear medicine and molecular imaging 48(5), 1371-1389 (2021). doi:10.1007/s00259-020-05094-1<br />Published by Springer-Verl., Heidelberg [u.a.]

Subjects :: residualizing label
Antibody-drug conjugate
MONOCLONAL-ANTIBODY
TRASTUZUMAB EMTANSINE T-DM1
Receptor, ErbB-2
medicine.drug_class
N-SUCCINIMIDYL
medicine.medical_treatment
Breast Neoplasms
Review Article
Monoclonal antibody
in-vivo
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Antibody drug conjugate
HER2 RECEPTOR EXPRESSION
HER2
medicine
Humans
Radiology, Nuclear Medicine and imaging
preclinical evaluation
single-domain antibody
ANTI-HER2 NANOBODY
biology
business.industry
EMITTING RADIOTHERAPEUTIC AGENT
Single domain antibody
General Medicine
Immunotherapy
Radioimmunotherapy
Single-Domain Antibodies
Affibody
3. Good health
Single-domain antibody
Pharmaceutical Preparations
Radioimmunodetection
030220 oncology & carcinogenesis
Drug delivery
Nanobody
Cancer research
biology.protein
Molecular imaging
Antibody
business

Full Text Access

Tools